https://www.selleckchem.com/products/pf-543.html
The achieved method advocated their applicability in routine quality control analysis of DIA formulations without interference of degraded product and excipients. Tofacitinib is an oral, small molecule Janus kinase inhibitor for the treatment of ulcerative colitis (UC). We aimed to estimate the overall incidence of safety events in patients with UC in a real-life population cohort for comparison with the tofacitinib UC clinical trial program. Clinical trial-like criteria were applied to an IBM MarketScan® claims database population-based
Like
Comment
Share
